SCHEMBL998440

SCHEMBL998440

CCOC(=O)c1cccc(NC(=O)N2CCCc3c([nH]c4ccccc34)C2)c1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 17/20 0.61
MAPT P10636 3/20 0.57
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53
THRB P10828 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL998854 0.95 TRPV1 (0.68) TRPV1MAPT
SCHEMBL997773 0.90 TRPV1 (0.63) TRPV1MAPT
SCHEMBL998951 0.85 TRPV1 (0.72) TRPV1
SCHEMBL996814 0.85 TRPV1 (0.69) TRPV1
SCHEMBL998299 0.83 TRPV1 (0.71) TRPV1
SCHEMBL1000937 0.82 TRPV1 (0.72) TRPV1MAPT
SCHEMBL999373 0.81 TRPV1 (0.88) TRPV1
SCHEMBL998273 0.81 TRPV1 (0.69) TRPV1MAPT
SCHEMBL999057 0.81 TRPV1 (0.89) TRPV1
SCHEMBL998142 0.79 TRPV1 (0.78) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637521-B1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO (JP) 2013-06-19 EP disclosed
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed
EP-1637521-A1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS TRPV1 2437/4885MAPT 4705/4885LMNA 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.